Category: Pharmaceutical Industry
-
U.S. appeals court grants Novartis short-term injunction in Entresto patent dispute with MSN: non-skilled-artisan testimony is key issue
The Federal Circuit has granted Novartis a few more days of Entresto exclusivity through a short-term injunction against MSN.
-
EWCA heard Pfizer, BioNTech appeal against Moderna’s COVID vaccine patent win
After losing a major ruling in the High Court of Justice in London last year, Pfizer and BioNTech asked the England & Wales Court of Appeal to overturn a decision finding a key Moderna COVID patent was valid and infringed.
-
Novartis denied injunctive relief against MSN in chronic heart failure patent fight: next stop emergency motion for injunction pending appeal?
Novartis cannot block rival MSN Pharmaceuticals from launching a generic version of its chronic heart failure treatment Entresto before its patent expires in November 2026, the District of Delaware has held.
-
Brain medtech firm Ceribell files ITC complaint against rival Natus Medical over seizure-detection tech patents
The Nasdaq-listed company has also sued its competitor in the District of Delaware, asserting six patents related to electroencephalography technologies used in seizure-detection devices.
-
UPC’s Court of Appeal: rehearings will rarely (if ever) happen, and UPC representatives MUST know EPO’s appellate case law
Context: Things have not gone well so far for Alexion Pharmaceuticals’ patent infringement actions against Amgen and Samsung Bioepis. Six months ago, the Unified Patent Court’s (UPC) Court of Appeal (CoA) affirmed (December 23, 2024 ip fray article) the Hamburg Local Division’s (LD) orders denying preliminary injunctions (PIs; officially called “provisional measures” in the UPC)….
-
Novartis and MSN settle part of chronic heart failure patent fight, but key patent remains
Novartis and MSN have settled one prong of their U.S. Entresto patent infringement dispute in the Federal Circuit, but the companies will continue to litigate over a second patent as Novartis strives to defend its corner of the chronic heart failure drug market.
-
Novo Nordisk lets key Ozempic patent lapse in Canada, despite being world’s second-largest semaglutide market
Novo Nordisk has continued to pay for a key Ozempic patent in several jurisdictions across the world, and even obtained an adjusted expiration date in the U.S., but the company stopped paying fees in Canada as far back as 2018, records show.
-
UPC Court of Appeal makes UK judge feel even better about his decision: Alexion v. Amgen & Samsung Bioepis
Mr Justice Meade of the High Court of Justice for England & Wales would have reached the same decision anyway, but likes the fact that the UPC CoA interpreted the claim language in the same way.
-
Illumina sues Element Biosciences in Delaware over gene sequencing patents
While this is Illumina’s first official suit against Element Biosciences, the latter has already faced challenges over its gene sequencing technology based on prior art from Illumina’s assets.
-
UPC Dusseldorf issues first decision on second medical use, hands win to Amgen in cholesterol patent dispute against Sanofi
The Dusseldorf Local Division has clarified how the UPC deals with second medical use in patent infringement proceedings, including considering the extent or significance of the allegedly infringing use, and whether an entity is “positively” or “negatively” influencing a market by encouraging infringement, or preventing a product from being used for patented use.